Related Experiment Video

Updated: Mar 26, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.7K

Persistent Challenges in Pediatric Pulmonary Hypertension

Rachel K Hopper1, Steven H Abman2, D Dunbar Ivy2

  • 1Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia, Philadelphia, PA.

Chest
|February 3, 2016
PubMed

Insights

Pediatric pulmonary hypertension presents unique challenges in diagnosis and treatment, differing significantly from adult forms. Advances are being made, but gaps in understanding clinical pediatric pulmonary hypertension persist.

Area of Science:

  • Pediatric cardiology and pulmonology
  • Vascular biology
  • Neonatal and pediatric critical care

Background:

  • Pulmonary hypertension (PH) and related pulmonary vascular diseases (PVDs) are associated with high morbidity and mortality in children.
  • Pediatric PH poses distinct challenges compared to adult PH, affecting etiology, classification, epidemiology, diagnosis, and treatment.
  • Current understanding of clinical pediatric PH necessitates further research to improve patient outcomes.

Purpose of the Study:

  • To review recent advances in the understanding and management of pediatric pulmonary hypertension.
  • To highlight key areas of progress in the field of pediatric pulmonary vascular diseases.
  • To identify persistent knowledge gaps in the clinical aspects of pediatric pulmonary hypertension.

Main Methods:

  • Literature review of recent advances in pediatric pulmonary hypertension.
  • Synthesis of current knowledge on pediatric pulmonary vascular diseases.
  • Identification of controversies and challenges in pediatric PH.

Main Results:

  • Significant differences exist between pediatric and adult pulmonary hypertension.
  • Recent advances have been made in understanding pediatric PH.
  • Persistent gaps in knowledge regarding pediatric PH etiology, classification, diagnosis, and treatment remain.

Conclusions:

  • Pediatric pulmonary hypertension requires specialized approaches distinct from adult care.
  • Continued research is crucial to address the remaining knowledge gaps in pediatric PH.
  • Improving outcomes for neonates, infants, and children with PH necessitates a deeper understanding of the disease.

Keywords:
pediatric cardiologypediatric pulmonarypulmonary hypertension

More Related Videos

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.8K
Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet09:22

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet

Published on: November 4, 2015

12.7K

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
827
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
733
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
369
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
547
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
4.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
633